Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Want to see HK:2197 full AI Analyst Report?
2197 Stock Chart & Stats
HK$2.37
>-HK$0.01(-2.10%)
At close: 4:00 PM EST
HK$2.37
>-HK$0.01(-2.10%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$3.20
Previous CloseN/A
Volume1.38M
Average Volume (3M)29.82M
Market Cap
HK$3.86B
Enterprise ValueHK$2.98B
Total Cash (Recent Filing)HK$286.15M
Total Debt (Recent Filing)HK$10.62M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,298,038,500
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-1.47
Price to Sales (P/S)775.86
P/FCF Ratio-13.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Technology PlatformOwning a proprietary trimer-tag platform is a durable R&D asset that differentiates the company in vaccine design. It supports repeated product generation, potential licensing or partnerships, and raises the long-term odds of successful candidates versus firms without platform technology.
Vaccine Development & Commercialization ExperiencePrior development and commercialization of vaccine candidates, including a COVID-19 program, indicates operational capability across R&D, manufacturing and regulatory processes. This built expertise and infrastructure can shorten timelines for future programs and aid partner collaborations.
Low Absolute Debt In 2025Relatively small absolute debt provides some near-term financial flexibility despite other weaknesses. Lower nominal leverage reduces immediate refinancing pressure and can make emergency capital injections or bridge financing easier to structure without onerous debt service.
Bears Say
Severe Revenue CollapseA ~93% revenue drop in 2025 represents a structural loss of commercial scale and revenue predictability. Such a collapse undermines pricing power, reduces reinvestment capacity for R&D and manufacturing, and materially raises the likelihood of further downsizing or asset sales to survive.
Persistent Negative Operating And Free Cash FlowSustained negative operating and free cash flows across multiple years signal chronic cash burn. This forces reliance on external financing, increasing dilution or covenant risk, and constrains the firm's ability to fund development, commercial scale-up, or respond to regulatory and market demands.
Consistently Negative Shareholder EquityNegative shareholder equity from 2022–2025 reflects accumulated losses that reduce solvency buffers. This impairs access to capital markets, elevates going-concern and refinancing risk, and can limit strategic choices such as M&A, partner deals, or debt-based liquidity solutions.
Clover Biopharmaceuticals Ltd. News
2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$0.19 and its highest was HK$3.20 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$3.86B.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 119 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.092.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,298,038,500 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of -HK$0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.563%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
589.23%
12-Months-Change
Fundamentals
Return on Equity
11.40%
Trailing 12-Months
Asset Growth
-41.03%
Trailing 12-Months
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
HBM Holdings Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---